DETERMINE news hub
Discover our latest updates including updates on our progress, site openings, and partnership initiatives.
Interested in learning more about the trial and how to get involved?
Our highlights
Collaboration for implementation of precision cancer medicine in Europe
PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials) aim to facilitate implementation of precision cancer medicine in Europe.
Patients with rare cancers given hope by UK-led ‘drug-match’ trial
Read in the Guardian about the DETERMINE trial's real-world impact for patients and how it's investigating whether treatments already licensed for more common cancers can benefit patients with rarer cancers.
In other news
2023
- Citeline: The Script Award categories 2023
- PRIME-ROSE: Official Opening of the Horizon EU Cancer Mission PRIME-ROSE project
- The Herald: Scotland cancer: First-of-its-kind trial to test new treatment
- The Independent: Scots with rare cancers to test new treatment in first-of-its-kind trial
- The Times: Scotland cancer patients will be first to try precision treatment
- The Standard: Scots with rare cancers to test new treatment in first-of-its-kind trial
- The National: Scots with rare cancers to test new treatment in first-of-its-kind trial
- Accelerate: Fair for AYA stamp
- Cancer Research Horizons: The DETERMINE trial: showcasing Cancer Research UK’s unique position in the pharma industry
- Cancer Research Horizons: Cancer Research UK joins European precision cancer medicine trial consortium
2022
- Cancer Research Horizons: Novartis joins Cancer Research UK trial for rare cancers
- Cancer Research Horizons: Precision medicine trial opens for rare adult and paediatric cancers
- Bionow: A fabulous night of accolades at the 2022 Bionow Awards Dinner
- Bionow: Introducing the 2022 Bionow Awards Shortlist!
2021
- The University of Manchester: Cancer researchers across the UK join forces to find drugs for rare cancers